Therapeutic potential of Lactobacillus plantarum HBUAS68394 in mitigating DSS-induced colitis | ||
| Egyptian Journal of Botany | ||
| Articles in Press, Accepted Manuscript, Available Online from 08 October 2025 | ||
| Document Type: Regular issue (Original Article) | ||
| DOI: 10.21608/ejbo.2025.363646.3211 | ||
| Authors | ||
| Fatma E. A. Yousef1; Mohamed A. Hussein* 2; Reda M. Taha1; Mai Ali Mwaheb1 | ||
| 1Botany Department, Faculty of Science, Fayoum University, Fayoum 63514, Egypt | ||
| 2Biotechnology Department, Faculty of Applied Heath Science Technology, October 6 University, Giza 28125, Egypt | ||
| Abstract | ||
| Inflammatory bowel diseases (IBD), including colitis, are characterized by persistent gastrointestinal inflammation, contributing to substantial health complications. Existing therapies frequently show restricted effectiveness and undesirable side effects, highlighting the need for alternative treatments. This study investigated the potential of Lactobacillus plantarum HBUAS68394 and celebrex in alleviating DSS-induced colitis in a murine model. The mice were treated with Dextran sulfate sodium (DSS) to induce colitis, followed by administration of L. plantarum and celebrex. Colon tissue integrity was evaluated via histology, PCR, and biochemical tests, measuring inflammatory cytokines (TNF-α, IL-1β, IL-12, NF-κB, HMGB1, cAMP, MPO), oxidative stress indicators (MDA, GSH, SOD), lipid profiles (cholesterol, triglycerides), and gut barrier markers (TFF3). Results demonstrated that L. plantarum and celebrex effectively reduced colitis severity in DSS-treated mice. Microscopic examination showed improved colon architecture, including intact crypts and diminished inflammatory infiltration. PCR results showed decreased levels of TNF-α, IL-1β, IL-12, cAMP, MPO, and MDA, as well as gene expression of NF-κB and HMGB1 proteins. Additionally, there was increased expression of the mucosal protective factor TFF3, as well as levels of GSH and SOD. Both treatments also improved lipid profiles by reducing plasma triglycerides and cholesterol levels and enhanced gut barrier function. The findings underscore the potential of L. plantarum HBUAS68394 and celebrex as therapeutic agents for managing colitis and enhancing colon health. This study provides a foundation for future clinical applications and personalized treatment strategies for inflammatory bowel diseases, aiming to improve patient outcomes and quality of life. | ||
| Keywords | ||
| DSS; Inflammatory cytokines; Lactobacillus plantarum; Oxidative stress biomarkers; TFF3; Ulcerative colitis | ||
|
Statistics Article View: 6 |
||
